

# Additional **information**

## **Independent registered public accounting firm**

Ernst & Young LLP  
Grand Rapids, Michigan

## **Transfer agent and registrar**

American Stock Transfer & Trust Company, LLC  
New York, New York

Shareholders needing information regarding their certificates or dividends should contact:

American Stock Transfer & Trust Company, LLC  
Operations Center  
6201 15th Avenue  
New York, New York 11219  
800 937 5449  
info@amstock.com

## **Investor contact**

Katherine A. Owen  
Vice President, Strategy and Investor Relations

## **Media contact**

Yin C. Becker  
Vice President, Communications, Public Affairs and Corporate Marketing

## **Business development contact**

Bryant S. Zanko  
Vice President, Business Development

## **Annual meeting**

The Annual Meeting of Shareholders of Stryker Corporation will be held at the Radisson Plaza Hotel at the Kalamazoo Center in Kalamazoo, Michigan, on Wednesday, May 1, 2019, at 2:00 p.m. ET.

## **Stock listing**

The company's common stock is traded on the New York Stock Exchange under the symbol SYK.

## **Form 10-K**

The company files an Annual Report on Form 10-K with the Securities and Exchange Commission. Shareholders may view the 2018 report at [www.stryker.com](http://www.stryker.com) or [www.sec.gov](http://www.sec.gov).

## **Forward-looking statements**

This Annual Review contains information that includes or is based on forward-looking statements within the meaning of the federal securities laws that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Such factors include, but are not limited to: weakening of economic conditions that could adversely affect the level of demand for our products; pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products; changes in foreign exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect U.S. Food and Drug Administration approval of new products; potential supply disruptions; changes in reimbursement levels from third-party payors; a significant increase in product liability claims; the ultimate total cost with respect to the Rejuvenate recall and other recall-related matters; the impact of investigative and legal proceedings and compliance risks; resolution of tax audits; the impact of the federal legislation to reform the United States healthcare system; costs to comply with medical device regulations; changes in financial markets; changes in the competitive environment; our ability to integrate acquisitions; and our ability to realize anticipated cost savings. Additional information concerning these and other factors is contained in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.